CORRECTING and REPLACING CytRx to Present at Roth 20th Annual OC Growth Stock Conference

Live Webcast on February 20 at 5 p.m. Pacific Time
LOS ANGELES--(Business Wire)--
The time listed in the subheadline and in the first graph (first
sentence) should read: 5 p.m. Pacific Time (sted 5 p.m. Eastern Time).

The corrected release reads:

CYTRX TO PRESENT AT ROTH 20TH ANNUAL OC GROWTH STOCK CONFERENCE

Live Webcast on February 20 at 5 p.m. Pacific Time

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company
engaged in the development and commercialization of human
therapeutics, today announced that CytRx President and CEO Steven A.
Kriegsman and Chief Scientific Officer Jack R. Barber, Ph.D., are
scheduled to present at the Roth 20th Annual Growth Stock Conference
on Wednesday, February 20, 2008 at 5 p.m. Pacific time. The
presentation will take place at the Ritz Carlton Hotel in Laguna
Niguel, California.

A live audio webcast and slide presentation will be available on
the Company's Web site at www.cytrx.com. Conference attendance is by
invitation only. To request an electronic invitation, contact a Roth
representative at (800) 678-9147 or via e-mail at conference@roth.com.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development
company engaged in the development of high-value human therapeutics.
The Company owns three clinical-stage compounds based on its small
molecule "molecular chaperone" co-induction technology. In September
2006, CytRx announced that arimoclomol was shown to be safe and
well-tolerated at all three doses tested in its Phase IIa clinical
trial in patients with ALS. The Company's Phase IIb clinical trial
with arimoclomol for ALS was placed on clinical hold in January 2008,
and the Company has announced its intention to work diligently to
respond as promptly as possible to the U.S. Food and Drug
Administration (FDA) following receipt of anticipated written
correspondence. The FDA has granted Fast Track designation and Orphan
Drug status to arimoclomol for the treatment of ALS, which has also
been granted orphan medicinal product status for the treatment of ALS
from the European Medicines Agency. The Company has announced plans to
commence a Phase II clinical trial for arimoclomol in stroke recovery
in the first half of 2008, subject to FDA clearance. The Company has
also announced plans to commence a Phase II clinical trial with its
next drug candidate, iroxanadine, for diabetic foot ulcers in the
second half of 2008, subject to FDA clearance. CytRx has recently
opened a research and development facility in San Diego. For more
information on the Company, visit www.cytrx.com.

About RXi Pharmaceuticals Corporation

Worcester, Massachusetts-based RXi Pharmaceuticals Corporation, a
majority-owned subsidiary of CytRx, is a discovery-stage
biopharmaceutical company pursuing the development and potential
commercialization of proprietary therapeutics based on RNA
interference (RNAi) for the treatment of human diseases. RXi
Pharmaceuticals' rxRNA(TM) compounds are distinct from the classic
siRNA compounds used by other companies developing RNAi therapeutics,
are up to 100x more active than conventional siRNA (depending on the
target site), are nuclease resistant and are readily manufactured. RXi
Pharmaceuticals believes it is well positioned to compete successfully
in the RNAi-based therapeutics market with its accomplished scientific
advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize
for his co-discovery of RNAi, a management team that is experienced in
commercializing products, and a strong early intellectual property
position.

Forward-Looking Statements

This press release may contain forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements involve risks and uncertainties that could
cause actual events or results to differ materially from the events or
results described in the forward-looking statements, including risks
or uncertainties described in CytRx's most recently filed SEC
documents, such as its most recent annual report on Form 10-K and any
current reports on Form 8-K filed since the date of the last Form
10-K. All forward-looking statements are based upon information
available to CytRx on the date the statements are first published.
CytRx undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.

CEOcast, Inc.
Dan Schustack, 212-732-4300
dschustack@ceocast.com

Copyright Business Wire 2008